Cancer Communications (Jun 2022)
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models
- Emma Polonio‐Alcalá,
- Sònia Solé‐Sánchez,
- Pau Muñoz‐Guardiola,
- Elisabet Megías‐Roda,
- Héctor Perez‐Montoyo,
- Marc Yeste‐Velasco,
- Jose Alfón,
- Jose Miguel Lizcano,
- Carles Domènech,
- Santiago Ruiz‐Martínez,
- Teresa Puig
Affiliations
- Emma Polonio‐Alcalá
- New Therapeutic Targets Laboratory (TargetsLab)—Oncology Unit Department of Medical Sciences University of Girona Girona 17003 Spain
- Sònia Solé‐Sánchez
- Ability Pharmaceuticals SL, Cerdanyola del Vallès Barcelona 08290 Spain
- Pau Muñoz‐Guardiola
- Ability Pharmaceuticals SL, Cerdanyola del Vallès Barcelona 08290 Spain
- Elisabet Megías‐Roda
- Ability Pharmaceuticals SL, Cerdanyola del Vallès Barcelona 08290 Spain
- Héctor Perez‐Montoyo
- Ability Pharmaceuticals SL, Cerdanyola del Vallès Barcelona 08290 Spain
- Marc Yeste‐Velasco
- Ability Pharmaceuticals SL, Cerdanyola del Vallès Barcelona 08290 Spain
- Jose Alfón
- Ability Pharmaceuticals SL, Cerdanyola del Vallès Barcelona 08290 Spain
- Jose Miguel Lizcano
- Protein Kinases and Signal Transduction Laboratory Department de Bioquímica i Biologia Molecular and Institut de Neurociències Universitat Autònoma de Barcelona, Bellaterra Barcelona 08193 Spain
- Carles Domènech
- Ability Pharmaceuticals SL, Cerdanyola del Vallès Barcelona 08290 Spain
- Santiago Ruiz‐Martínez
- New Therapeutic Targets Laboratory (TargetsLab)—Oncology Unit Department of Medical Sciences University of Girona Girona 17003 Spain
- Teresa Puig
- New Therapeutic Targets Laboratory (TargetsLab)—Oncology Unit Department of Medical Sciences University of Girona Girona 17003 Spain
- DOI
- https://doi.org/10.1002/cac2.12282
- Journal volume & issue
-
Vol. 42,
no. 6
pp. 567 – 571
Abstract
No abstracts available.Keywords
